Surrozen, Inc. · NASDAQ:SRZN
Surrozen — SPAC Merger (April 2021)
31 slides from Surrozen's SPAC merger presentation, Apr 15, 2021
Slide 1: The Wnt Company – Powering Regeneration 2021
The Wnt Company – Powering Regeneration 2021 © 2021 Surrozen, Inc. Exhibit 99.2
Slide 2: Legal Disclaimers
Legal Disclaimers © 2021 Surrozen, Inc. This presentation (“Presentation”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination’”) between Consonance-HFW Acquisition Corp. (“CHFW”)
Slide 3: Legal Disclaimers
Legal Disclaimers © 2021 Surrozen, Inc. Additional Information. In connection with the proposed Business Combination, CHFW intends to file with the SEC a registration statement on Form S-4 , which will include a prospectus with respect to the securities of CHFW to be issued in connection with the bu
Slide 4: Experienced Management and World-Renowned Scientific Advisors
Craig Parker, MBA CEO and President Trudy Vanhove, MD, Ph.D., MBA Chief Medical Officer Charles Williams Chief Financial Officer Wen-Chen Yeh, MD, Ph.D. Chief Scientific Officer Reza Afkhami, MBA VP, Corporate Development and Strategy Yang Li, Ph.D. SVP, Biology Christine McKinley VP, Human Resource
Slide 5: Potential First-in-Class Pioneers in Wnt Signaling Therapeutics
Potential First-in-Class Pioneers in discovering and developing therapeutics that selectively activate the Wnt signaling pathway Highlights © 2021 Surrozen, Inc. Potential for Establishing a New Treatment Paradigm in a Broad Spectrum of Therapeutic Areas Tissue selective regeneration for GI tract, l
Slide 6: Broad Spectrum of Serious Diseases Can Be Targeted with Wnt Biology
Broad Spectrum of Serious Diseases Can Be Targeted with Wnt Biology Potential for Disease Modifying Therapeutics that Can Regenerate Healthy Tissue © 2021 Surrozen, Inc. We believe that Wnt biology offers a mechanism to regenerate healthy tissue and improve organ function Cochlea (Inner Ear Hair Cel
Slide 7: Our Novel Approach Overcomes Previous Challenges
© 2021 Surrozen, Inc. Our Novel Approach Overcomes Previous Challenges Technologies, Expertise and Strategy Help Establish a New Paradigm Our antibodies have desirable drug-like properties: Technologies confer desirable PK, stability and manufacturability properties Our mechanisms mimic normal physi
Slide 8: Integrated, Repeatable, Extendable Wnt Therapeutics Platform
Founded and operated by key thought leaders within Wnt scientific field Deep understanding of Wnt and disease biology Two antibody technologies: SWAPs and SWEETS Selective Wnt-activating therapeutics to promote tissue regeneration Patents filed on additional novel Wnt technologies Wnt signaling defi
Slide 9: Validation of Our Prominent Role in Wnt Biology
Potential first synthetic, soluble Wnt mimetics The requirement for multivalent binding to confer potency and selectivity Multi-valent bi-specific antibody formats for optimal activity R-Spondin mimetic technology and potential role in regeneration Discoveries form the foundation of our proprietary
Slide 10: Proprietary Technologies Enable Potent, Selective Wnt Signaling
© 2021 Surrozen, Inc. Proprietary Technologies Enable Potent, Selective Wnt Signaling SWAPs & SWEETS SWAP Technology SWEETS Technology anti-Lrp VHH anti-Fzd IgG effector-less hIgG1 Antibody Based Bi-Specific Mimics natural Wnt in activating Wnt signaling Applied in disease states with deficient Wnt
Slide 11: Proprietary, Wholly-Owned Portfolio
Proprietary, Wholly-Owned Portfolio Application of Our Discoveries and Technologies Has Been Highly Productive © 2021 Surrozen, Inc. Moderate to Severe IBD SZN-1326 Fzd5/Lrp6, SWAP SZN-043 E3/ASGR1,SWEETS First in Human 2022 Severe Alcoholic Hepatitis First in Human 2022 Retinal Vasculature Diabetic
Slide 12: SZN-1326 Moderate to Severe IBD
© 2021 Surrozen, Inc. anti-Lrp6 VHH anti-Fzd IgG (Fzd5) effector-less hIgG1 SZN-1326 Moderate to Severe IBD
Slide 13: SZN-1326 – Intestine Targeted Epithelial Restoration
SZN-1326 – Intestine Targeted Epithelial Restoration Mechanism Suggests a Potential New Treatment Paradigm in Inflammatory Bowel Disease © 2021 Surrozen, Inc. Selective Wnt activation Epithelial repair Functional improvement Mechanism 2022 – First in human 2022 – Safety 2023 – Phase 1b proof-of-conc
Slide 14: SZN-1326 – Potential to Transform Treatment Paradigm in IBD
SZN-1326 – Potential to Transform Treatment Paradigm in IBD © 2021 Surrozen, Inc. NEED FOR RAPID INDUCTION: current anti-inflammatory biologics can take months to induce clinical remission NEED FOR BETTER EFFICACY ESPECIALLY MUCOSAL HEALING: anti-inflammatory biologics achieve clinical remission in
Slide 15: SZN-1326 – Restores Wnt Signaling in Damaged Intestine
SZN-1326 – Restores Wnt Signaling in Damaged Intestine © 2021 Surrozen, Inc. No DSS DSS anti-GFP DSS + SZN-1326 Axin2 Selective Binding Profile Restores Wnt Signaling in Damaged Intestinal Epithelium Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Fzd10 Fzd9
Slide 16: SZN-1326 – Repairs Damaged Colon Epithelium
SZN-1326 – Repairs Damaged Colon Epithelium © 2021 Surrozen, Inc. Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Effects of SZN-1326 Administration Repairs damaged colon epithelium in acute and chronic colon injury models Restores key cell lineages including
Slide 17: SZN-1326 – Reduces Inflammatory Cytokines
SZN-1326 – Reduces Inflammatory Cytokines © 2021 Surrozen, Inc. Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Reduces key inflammatory cytokines induced by DSS and implicated in human IBD Results reproducible in both localized colon tissue and systemic seru
Slide 18: SZN-1326 – Reduces Disease Activity
SZN-1326 – Reduces Disease Activity © 2021 Surrozen, Inc. Selective Wnt activation Epithelial repair Inflammation reduction Functional improvement Disease Activity Index (DAI) at Day 10 (BW, fecal score) Body Weight Percent Change at Day 10 Fecal Score at Day 10 SZN-1326 SZN-1326 SZN-1326 SZN-1326 d
Slide 19: Initial Clinical Development Focus on Ulcerative Colitis
Healthy Up to 60 Australia PD markers Initial Clinical Development Focus on Ulcerative Colitis Potential to Expand Into Additional IBD Indications © 2021 Surrozen, Inc. Placebo-controlled SAD/MAD in HV: subjects will be dosed for up to 12 weeks IV and SQ (lower dose levels only) either weekly or biw
Slide 20: SZN-043 Severe Liver Disease
© 2021 Surrozen, Inc. Mutated RSPO2 Anti-ASGR1 IgG Effector-less hIgG1 SZN-043 Severe Liver Disease
Slide 21: SZN-043 – Liver Specific Wnt Activation and Regeneration
SZN-043 – Liver Specific Wnt Activation and Regeneration Potential for First Approved Treatment for Severe Alcoholic Hepatitis © 2021 Surrozen, Inc. Selective Wnt activation Specific hepatocyte proliferation Functional improvement Mechanism 2022 - First in human 2023 – Phase 1b in severe AH Potentia
Slide 22: SZN-043 – Potential to Significantly Improve Outcomes in Severe Alcoholic Hepatitis
SZN-043 – Potential to Significantly Improve Patient Outcomes in Severe Alcoholic Hepatitis © 2021 Surrozen, Inc. NO APPROVED DRUGS: SOC: steroids HIGH MORTALITY: 90-day mortality of 30% due to hepatocyte loss and impaired regeneration leading to liver and organ failure HEPATOCYTE REGENERATION INCRE
Slide 23: SZN-043 Selectively Stimulates Hepatocyte Proliferation
SZN-043 Selectively Stimulates Hepatocyte Proliferation Hepatocyte Proliferation Results in Rapid Improvement in Liver Function © 2021 Surrozen, Inc. Anti-GFP SZN-043 Ki-67 HNF4α Overlay Selective Wnt activation Hepatocyte Proliferation SZN-043 induces Axin-2 expression selectively in the liver in n
Slide 24: SZN-043 Reduces Markers of Liver Injury and Inflammation
SZN-043 Reduces Markers of Liver Injury and Inflammation Activity in Alcohol Injury Model Support Clinical Development Path © 2021 Surrozen, Inc. AST:ALT ratio Ammonia Liver IL6 Selective Wnt activation Hepatocyte Proliferation Functional Improvement Surrozen established a rodent model of alcohol-in
Slide 25: Clinical Development Plan Provides Fast Path to POC and Approval
HV/Early cirrhosis 30-45 US PD markers Severe Alcoholic Hepatitis Up to 30 US 7day Lille score, MELD score PD markers Clinical Development Plan Provides Fast Path to POC and Approval © 2021 Surrozen, Inc. Short-term IV treatment for rapid hepatocyte regeneration in an acute setting of hepatocyte los
Slide 26: Wnt and Ocular Diseases
Wnt and Ocular Diseases Broad Set of High Prevalence Diseases © 2021 Surrozen, Inc. Fzd4 maintains and restores the blood-retina barrier SWAP antibodies activating Fzd4 inhibited vascular leakage 1.5M patients in the US Wnt involved in retinal pigment epithelial (RPE) cells and photoreceptor regener
Slide 27: Near Term Outlook and Potential Milestones
© 2021 Surrozen, Inc. SZN-1326 INTESTINE SZN-043 LIVER RESEARCH PROGRAMS 2021 Complete IND-enabling Toxicology Studies 2021 Complete IND-enabling Toxicology Studies 2022 Phase 1a in Healthy Volunteers 2023 Phase 1b in Ulcerative Colitis Patients 2022 Phase 1a in Healthy Volunteers and Hepatic Impair
Slide 28: Highlights of Business Combination
Highlights of Business Combination © 2020 Surrozen, Inc. Transaction Summary Surrozen, Inc. (“Surrozen”) and Consonance-HFW Acquisition Corp. (“CHFW”) expected to merge pursuant to a Business Combination Agreement Expected post transaction equity value of $432 million, assuming a CHFW share price of
Slide 29: Pro Forma Valuation and Ownership; Sources and Uses
© 2021 Surrozen, Inc. PRO FORMA VALUATION AND OWNERSHIP SOURCES USES CHFW Trust Equity2 $92.0 Surrozen Balance Sheet Cash6 38.5 Proceeds from PIPE Financing 120.2 Surrozen Shareholder Equity Rollover 200.0 Total Transaction Sources $450.7 Includes shares subject to outstanding Surrozen equity awards
Slide 30: Potential First-in-Class Pioneers in Wnt Signaling Therapeutics
Potential First-in-Class Pioneers in discovering and developing therapeutics that selectively activate the Wnt signaling pathway Highlights © 2021 Surrozen, Inc. Potential for Establishing a New Treatment Paradigm in a Broad Spectrum of Therapeutic Areas Tissue selective regeneration for GI tract, l
Slide 31: The Wnt Company - Powering Regeneration 2021
The Wnt Company - Powering Regeneration 2021 © 2021 Surrozen, Inc.